Labcorp Holdings Inc. (LH) · Sep 22, 2026 · Guidance

Labcorp reaffirms 2026–29 outlook despite looming Medicare lab cuts

Guidance reaffirmed — 2026–2029 outlook unchanged despite preliminary 2027–2029 payment pressure

CMS’s preliminary lab rates threaten reimbursement, but Labcorp says the risk was already embedded in its long-term outlook.

Labcorp is trying to grow through specialty diagnostics, biopharma laboratory services, personalized health, and technology while managing pressure on traditional laboratory reimbursement. Its September 10, 2026 outlook targeted 5%–8% annual revenue growth and 8.5%–11.5% adjusted EPS growth through 2029, with margin expansion and cash-flow growth also expected.

The immediate signal is confirmation, not a reset. CMS’s preliminary Clinical Laboratory Fee Schedule rates point to significant PAMA-related pressure for 2027–2029, but Labcorp says that continuation of this pressure was already incorporated into the outlook issued 12 days earlier. 〔0〕

The new information is the policy detail, not a change in Labcorp’s plan. CMS has released preliminary rates and is still accepting public comment before finalizing them, so the filing does not quantify the eventual earnings impact or indicate that the company’s long-term targets need to change.

The risk is pushed into 2027 guidance rather than resolved. Labcorp says it is still evaluating the rates and will provide more detail when it issues 2027 financial guidance in February 2027. 〔1〕

Bottom line: This filing is a mixed update: reimbursement pressure looks real, but it was anticipated and does not currently force a change to Labcorp’s 2026–2029 outlook. The meaningful test moves to the February 2027 guidance.

What to watch next

2027 guidance, February 2027

Original filing on SEC EDGAR

More Labcorp Holdings Inc. news

Labcorp reaffirms 2026–29 outlook despite looming Medicare lab cuts | LH Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.